Latest Healthcare News

EVE Health Group has placed its first commercial purchase order for Dyspro™, a cannabinoid-based pharmaceutical targeting painful menstruation, signaling a key step toward market entry. The product is set for manufacturing and distribution within weeks, tapping into a rapidly growing global women’s health market.

Nanosonics has launched trophon3, its next-generation ultrasound disinfection device, alongside a software upgrade for existing users, promising faster cycles and enhanced digital integration.

Imugene Limited has received a $5.87 million R&D tax refund, reinforcing its capacity to advance clinical trials in immuno-oncology. This funding milestone supports the development of its innovative cancer therapies, including CAR T cell treatments and oncolytic virotherapy.

TruScreen Group Limited has corrected an administrative error in its Share Purchase Plan allocations, ensuring shareholders receive their proper pro-rata entitlements ahead of a key special meeting.

Enlitic has completed its $10 million capital raise, triggering a $2 million advance payment from GE HealthCare and cementing a strategic collaboration with significant revenue potential.

Acrux Limited has secured a further $0.46 million advance on its FY25 R&D Tax Incentive, bringing total advances to $2.19 million and supporting its pharmaceutical product development and working capital needs.

Pro Medicus has secured a landmark 10-year, A$170 million contract to deploy its cloud-based Visage 7 imaging platform across UCHealth’s extensive hospital network in the US Rocky Mountain region.

Pro Medicus Limited has renewed a significant five-year contract with Franciscan Missionaries of Our Lady Health System, marking a strategic shift to cloud-based medical imaging solutions and promising new revenue streams.

PainChek Limited reports a robust quarter with a 10% rise in annual recurring revenue and expanding global client base, underpinned by strong licence retention and positive clinical validation.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

Universal Biosensors will lift its trading suspension following the announcement of a non-binding term sheet for a senior secured loan facility, signaling a potential boost to its financial position.